A number of research firms have changed their ratings and price targets for ProNAi Therapeutics (NASDAQ: DNAI): 8/21/2015 – ProNAi Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $36.00 price target on the stock. 8/10/2015 – ProNAi Therapeutics is now covered by analysts at Bank of America. They set […]
